Plasma antioxidant capacity in two cases of tyrosinaemia type 1: one case treated with NTBC.
Bird
S
S
Clinical Biochemistry Department, UMDS, Guy's Hospital, London, UK.
Miller
N J
NJ
Collins
J E
JE
Rice-Evans
C A
CA
D015111:4-Hydroxyphenylpyruvate Dioxygenase / Q000037:antagonists & inhibitors; D000592:Amino Acid Metabolism, Inborn Errors / Q000178:diet therapy / Q000188:drug therapy* / Q000378:metabolism; D000975:Antioxidants / Q000378:metabolism*; D001663:Bilirubin / Q000378:metabolism; D003512:Cyclohexanones / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D009579:Nitrobenzoates / Q000627:therapeutic use*; D012709:Serum Albumin / Q000378:metabolism; D014443:Tyrosine / Q000097:blood*
D000975:Antioxidants; D003512:Cyclohexanones; D004791:Enzyme Inhibitors; D009579:Nitrobenzoates; D012709:Serum Albumin; D014443:Tyrosine; D015111:4-Hydroxyphenylpyruvate Dioxygenase; C077073:nitisinone; D001663:Bilirubin